Clover has been informed of the study results by the South Australian Health and Medical Research Institute (SAHMRI), which conducted the double-blind randomised controlled clinical trial. The results of the N3RO study, one of the larger of its type conducted in the world, have been published in the New England Journal of Medicine. Clover Corporation is a science-based bioactives company developing novel nutritional applications of Docosahexaenoic Acid (DHA).

It donated the DHA emulsion to the study, but was not involved in the study design, conduct or report preparation. The N3RO study involved 1273 babies from Australia, New Zealand and Singapore, born at less than 29 weeks of gestational age, half who received DHA supplementation and half who received a placebo. The potential cognitive benefits of the high DHA emulsion were assessed once participants reached five years of age in a subgroup of 656 children who were enrolled from the 5 larger recruitment centres.